Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass
Open accessThe DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and neogenesis and promotion of beta-cell survival. These effects have tremendous implication in the treatment of T2D because they directly address one of the basic defects in T2D, that is, beta-cell failure. In human diabetes, however, evidence that the GLP-1-based drugs alter the course of beta-cell function remains to be found. Several questions surrounding the risks and benefits of GLP-1-based therapy for the diabetic beta-cell mass are discussed in this review and require further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 GLP-1 or Exendin-4 (Ex-4) activates beta-cells regeneration in vivo. The aim was to investigate in the rat model of neonatal beta-cell regeneration (nSTZ model), the capacity of in vivo treatments with GLP-1 or Ex-4 to promote beta-cell regeneration. To this end, nSTZ rats from the Wistar strain (W) were submitted to GLP-1 or Ex-4 administration from postnatal day 2 to day 6 only, and their beta-cell masses were tested on day 7 (a) and (b). In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, total beta-cell masses per pancreas were both significantly increased (***P < .001) as compared with values in untreated nSTZ rats, representing, respectively, 51% and 71% of the control Wistar beta-cell mass, while nSTZ beta-cell mass represented only 21% of the control Wistar value. Beta-cell BrdU labeling index (c) in the untreated nSTZ rats was found to be significantly increased (P < .001) as compared with Wistar group. In the nSTZ/GLP-1 and nSTZ/Ex-4 groups, it was similarly increased. A representative figure is given with double immunostaining for BrdU and insulin in 7-day-old nSTZ rats (magnification ×1000). To estimate activation of neogenesis (d) and (e), the number of single beta-cells incorporated into the duct epithelium and the number of beta-cell clusters budding from ducts were quantified. The number of isolated beta-cell within pancreatic tissue of nSTZ rats represented 185% of Wistar value and the number of beta-cell buds in pancreatic tissue in nSTZ rats represented 106% of Wistar value. These two parameters were strongly increased in nSTZ/GLP-1 and nSTZ/Ex-4 rats as compared to untreated nSTZ rats (***P < .001). A representative figure is given with indirect immunoperoxydase staining for insulin in 7 day-old nSTZ/GLP-1 rats (magnification ×1000). Adapted from Tourrel et al. [83].](https://figures.cochat.ai/paper-figures/c544b531910d4ce2ba066166796bc3e4/activation-of-the-glp-1-receptor-signalling-pathway-a-relevant-strategy-to-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This not only prevents the phosphorylation of JNK but also promotes the phosphorylation of STAT3, aiding the shift of macrophages to an anti-inflammatory M2 phenotype.327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [327]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Specifically, activation of GLP-1R leads to an increase in cAMP levels, which in turn activates PKA, a widely regulating enzyme of cellular functions, capable of phosphorylating a variety of target proteins, thereby initiating the PKA/CREB signaling pathway.326,327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [327]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998) · Nature · doi:10.1038/24884 · Cited by 1,969
A Family of cAMP-Binding Proteins That Directly Activate Rap1
Kawasaki, H., Springett, G. M., Mochizuki, N., Toki, S., Nakaya, M., Matsuda, M., Housman, D. E., & Graybiel, A. M. (1998) · Science · doi:10.1126/science.282.5397.2275 · Cited by 1,362
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
IPF1, a homeodomain-containing transactivator of the insulin gene.
Ohlsson, H., Karlsson, K., & Edlund, T. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06109.x · Cited by 888
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · cited 1×
“GLP-1R activation reduces beta-cell apoptosis in purified rodent and human islets as well as beta-cell lines after exposure to many cytotoxic agents, including reactive oxygen species, glucose, free fatty acid, palmitate, cytokines, tumor necrosis factor-α (TNF-α), immunosuppressive reagents, and dexamethasone [66].”
BackgroundRim is a putative Rab3 effector in regulating synaptic-vesicle fusion
Wang, Y., Okamoto, M., Schmitz, F., Hofmann, K., & Südhof, T. C. (1997) · Nature · doi:10.1038/41580 · Cited by 684
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589 · cited 1×
“A role for endogenous GLP-1 in prevention of beta-cell death was demonstrated by the increased susceptibility to streptozotocin-induced apoptosis in GLP-1R knockout mice; conversely, streptozotocininduced apoptosis was significantly reduced by coadministration of Ex-4 [67].”
BackgroundKitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W., Wright, C. V. E., White, M. F., Arden, K. C., & Accili, D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16857 · Cited by 580
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2
Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed, J., Walker, J., Lin, X., White, M., & Montminy, M. (2003) · Genes & Development · doi:10.1101/gad.1097103 · Cited by 543
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 1×
“Ex-4 treatment of Lepdb/Lepdb mice decreases activation of caspase-3 and prevents beta-cell apoptosis through PKB and MAPK [85] and infusion with GLP-1 drastically reduced the number of apoptotic beta cells in islets of Zucker diabetic rats [65].”
BackgroundGlucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 483
cAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 1×
“in the regulation of docking and fusion of insulin-containing vesicles to the plasma membrane [39, 40].”
BackgroundKitamura, T., Nakae, J., Kitamura, Y., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200216857 · Cited by 479
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Functional interaction of the active zone proteins Munc13-1 and RIM1 in synaptic vesicle priming
Betz, A., Thakur, P., Junge, H. J., Ashery, U., Rhee, J.-S., Scheuss, V., Rosenmund, C., Rettig, J., & Brose, N. (2001) · Neuron · doi:10.1016/s0896-6273(01)00272-0 · Cited by 425
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413
Buteau, J., Foisy, S., Joly, E., & Prentki, M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.124 · Cited by 411
Tourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Self-citationInterplay of Nutrients and Hormones in the Regulation of Insulin Release*
PIPELEERS, D. G., SCHUIT, F. C., IN’T VELD, P. A., MAES, E., HOOGHE-PETERS, E. L., WINKEL, M. V. D., & GEPTS, W. (1985) · Endocrinology · doi:10.1210/endo-117-3-824 · Cited by 358
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Islet Inflammation in Type 2 Diabetes
Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Perren, A., & Ehses, J. A. (2008) · Diabetes Care · doi:10.2337/dc08-s243 · Cited by 334
Dore, D. D., Seeger, J. D., & Arnold Chan, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 326
Liu, Z., & Habener, J. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706105200 · Cited by 326
Zhou, J., Wang, X., Pineyro, M. A., & Egan, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Wang, Q., & Brubaker, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0828-3 · Cited by 312
Kang, G., Joseph, J. W., Chepurny, O. G., Monaco, M., Wheeler, M. B., Bos, J. L., Schwede, F., Genieser, H.-G., & Holz, G. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211682200 · Cited by 298
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
Self-citationA novel lipid-anchored A-kinase Anchoring Protein facilitates cAMP-responsive membrane events
Fraser, I. D. C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.8.2261 · Cited by 284
Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281
Mashima, H., Ohnishi, H., Wakabayashi, K., Mine, T., Miyagawa, J., Hanafusa, T., Seno, M., Yamada, H., & Kojima, I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118591 · Cited by 278
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
Gromada, J., Holst, J. J., & Rorsman, P. (1998) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s004240050558 · Cited by 258
Buteau, J., Foisy, S., Rhodes, C. J., Carpenter, L., Biden, T. J., & Prentki, M. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2237 · Cited by 252
Arbiter of differentiation and death: Notch signaling meets apoptosis
Miele, L., & Osborne, B. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199912)181:3<393::aid-jcp3>3.0.co;2-6 · Cited by 250
Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas
Tornehave, D., Kristensen, P., Rømer, J., Knudsen, L. B., & Heller, R. S. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.951319 · Cited by 248
Lonart, G., Schoch, S., Kaeser, P. S., Larkin, C. J., Südhof, T. C., & Linden, D. J. (2003) · Cell · doi:10.1016/s0092-8674(03)00727-x · Cited by 247
Li, Y., Cao, X., Li, L.-X., Brubaker, P. L., Edlund, H., & Drucker, D. J. (2005) · Diabetes · doi:10.2337/diabetes.54.2.482 · Cited by 247
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242
Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J. L., Lu, J.-C., & Olefsky, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710402105 · Cited by 239
Hulme, J. T., Lin, T. W.-C., Westenbroek, R. E., Scheuer, T., & Catterall, W. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135335100 · Cited by 229
Hui, H., Wright, C., & Perfetti, R. (2001) · Diabetes · doi:10.2337/diabetes.50.4.785 · Cited by 223
Shiota, C., Larsson, O., Shelton, K. D., Shiota, M., Efanov, A. M., Høy, M., Lindner, J., Kooptiwut, S., Juntti-Berggren, L., Gromada, J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206757200 · Cited by 222
TSUBOI, T., SILVA XAVIER, G. D., HOLZ, G. G., JOUAVILLE, L. S., THOMAS, A. P., & RUTTER, G. A. (2003) · Biochemical Journal · doi:10.1042/bj20021288 · Cited by 216
Kato, I., Yamamoto, Y., Fujimura, M., Noguchi, N., Takasawa, S., & Okamoto, H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.1869 · Cited by 211
GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells
Egan, J. M., Bulotta, A., Hui, H., & Perfetti, R. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.357 · Cited by 209
Piccolo, a Ca2+ Sensor in Pancreatic β-Cells
Fujimoto, K., Shibasaki, T., Yokoi, N., Kashima, Y., Matsumoto, M., Sasaki, T., Tajima, N., Iwanaga, T., & Seino, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m210146200 · Cited by 197
Trumper, A., Trumper, K., & Horsch, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740233 · Cited by 193
Anchoring of protein kinase A facilitates hormone-mediated insulin secretion
Lester, L. B., Langeberg, L. K., & Scott, J. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14942 · Cited by 193
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189
Light, P. E., Manning Fox, J. E., Riedel, M. J., & Wheeler, M. B. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0084 · Cited by 188
Meier, J. J., Lin, J. C., Butler, A. E., Galasso, R., Martinez, D. S., & Butler, P. C. (2006) · Diabetologia · doi:10.1007/s00125-006-0308-2 · Cited by 181
Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178 · cited 2×
“Nevertheless, GLP-1 triggers expression and nuclear localization of PDX-1 involves the phosphorylation of FoxO1 via transactivation of the EGFR and PI-3K/PKB pathway, resulting in deactivation and nuclear exclusion of FoxO1 and consequent disinhibition of Foxa2-dependent pdx-1 gene promoter activity [14, 15].”
BackgroundNie, Y., Nakashima, M., Brubaker, P. L., Li, Q.-L., Perfetti, R., Jansen, E., Zambre, Y., Pipeleers, D., & Friedman, T. C. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7456 · Cited by 170
Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169 · cited 1×
“Ex-4 has also been administered to NOD mice alone or in combination with different immune modulators, lisofylline [98], antilymphocyte serum [99], or anti-CD3 immunotherapy [100]: the highest frequency of diabetes remission was observed in animals that received the combination treatments, suggesting a beneficial syner…”
BackgroundKang, G., Chepurny, O. G., Malester, B., Rindler, M. J., Rehmann, H., Bos, J. L., Schwede, F., Coetzee, W. A., & Holz, G. G. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.107391 · Cited by 167
Ferdaoussi, M., Abdelli, S., Yang, J.-Y., Cornu, M., Niederhäuser, G., Favre, D., Widmann, C., Regazzi, R., Thorens, B., Waeber, G., et al. (2008) · Diabetes · doi:10.2337/db07-1214 · Cited by 167
Control of Insulin mRNA Stability in Rat Pancreatic Islets
Tillmar, L., Carlsson, C., & Welsh, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108340200 · Cited by 162
Glucagon-Like Peptide-1 Regulates the Beta Cell Transcription Factor, PDX-1, in Insulinoma Cells
Wang, X., Cahill, C. M., Piñeyro, M. A., Zhou, J., Doyle, M. E., & Egan, J. M. (1999) · Endocrinology · doi:10.1210/endo.140.10.7158 · Cited by 160
Koehler, J. A., Baggio, L. L., Lamont, B. J., Ali, S., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db09-0626 · Cited by 159
Cure of Overt Diabetes in NOD Mice by Transient Treatment With Anti-Lymphocyte Serum and Exendin-4
Ogawa, N., List, J. F., Habener, J. F., & Maki, T. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1700 · Cited by 155
Friedrichsen, B. N., Neubauer, N., Lee, Y. C., Gram, V. K., Blume, N., Petersen, J. S., Nielsen, J. H., & Møldrup, A. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06160 · Cited by 149
Skoglund, G., Hussain, M. A., & Holz, G. G. (2000) · Diabetes · doi:10.2337/diabetes.49.7.1156 · Cited by 144
Wang, X., Zhou, J., Doyle, M. E., & Egan, J. M. (2001) · Endocrinology · doi:10.1210/endo.142.5.8128 · Cited by 142
The GK rat beta-cell: A prototype for the diseased human beta-cell in type 2 diabetes?
Portha, B., Lacraz, G., Kergoat, M., Homo-Delarche, F., Giroix, M.-H., Bailbé, D., Gangnerau, M.-N., Dolz, M., Tourrel‐Cuzin, C., & Movassat, J. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.06.013 · Cited by 140
Self-citationMacDonald, P. E., Wang, X., Xia, F., El-kholy, W., Targonsky, E. D., Tsushima, R. G., & Wheeler, M. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307612200 · Cited by 129
A Role for Activin A and Betacellulin in Human Fetal Pancreatic Cell Differentiation and Growth
Demeterco, C., Beattie, G. M., Dib, S. A., Lopez, A. D., & Hayek, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6848 · Cited by 129
Kim, B.-J., Park, K.-H., Yim, C.-Y., Takasawa, S., Okamoto, H., Im, M.-J., & Kim, U.-H. (2008) · Diabetes · doi:10.2337/db07-0443 · Cited by 123
Exenatide and rare adverse events.
Ahmad, S. R., & Swann, J. (2008) · PubMed · Cited by 122
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D’Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 118
Ontogeny of Regeneration of β-Cells in the Neonatal Rat after Treatment with Streptozotocin
Thyssen, S. M., Arany, E. J., & Hill, D. J. (2006) · Endocrinology · doi:10.1210/en.2005-0396 · Cited by 115
Tanabe, K., Liu, Z., Patel, S., Doble, B. W., Li, L., Cras-Méneur, C., Martinez, S. C., Welling, C. M., White, M. F., Bernal-Mizrachi, E., et al. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060037 · Cited by 115
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115 · cited 16×
“In addition, FoxO1 and PDX-1 mutually exclude each other from the nucleus of the beta cell [14].”
BackgroundInfluentialMovassat, J., Beattie, G. M., Lopez, A. D., & Hayek, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020137 · Cited by 110
Self-citationWideman, R. D., Yu, I. L. Y., Webber, T. D., Verchere, C. B., Johnson, J. D., Cheung, A. T., & Kieffer, T. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600655103 · Cited by 108
Nakazaki, M., Crane, A., Hu, M., Seghers, V. J., Ullrich, S., Aguilar‐Bryan, L., & Bryan, J. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3440 · Cited by 108
Kim, S.-J., Nian, C., Doudet, D. J., & McIntosh, C. H. S. (2009) · Diabetes · doi:10.2337/db08-1101 · Cited by 106
Cornu, M., Modi, H., Kawamori, D., Kulkarni, R., Joffraud, M., & Thorens, B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091116 · Cited by 102
Tsunekawa, S., Yamamoto, N., Tsukamoto, K., Itoh, Y., Kaneko, Y., Kimura, T., Ariyoshi, Y., Miura, Y., Oiso, Y., & Niki, I. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0148 · Cited by 100
Pancreatic duct replication is increased with obesity and type 2 diabetes in humans
Butler, A. E., Galasso, R., Matveyenko, A., Rizza, R. A., Dry, S., & Butler, P. C. (2010) · Diabetologia · doi:10.1007/s00125-009-1556-8 · Cited by 99
Zhou, J., Pineyro, M. A., Wang, X., Doyle, M. E., & Egan, J. M. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10143 · Cited by 95
Klinger, S., Poussin, C., Debril, M.-B., Dolci, W., Halban, P. A., & Thorens, B. (2008) · Diabetes · doi:10.2337/db07-1414 · Cited by 86
Targeted Protein Kinase A and PP-2B Regulate Insulin Secretion through Reversible Phosphorylation
Lester, L. B., Faux, M. C., Nauert, J. B., & Scott, J. D. (2001) · Endocrinology · doi:10.1210/endo.142.3.8023 · Cited by 86
Knoch, K.-P., Meisterfeld, R., Kersting, S., Bergert, H., Altkrüger, A., Wegbrod, C., Jäger, M., Saeger, H., & Solimena, M. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2005.12.008 · Cited by 84
Zhang, J., Tokui, Y., Yamagata, K., Kozawa, J., Sayama, K., Iwahashi, H., Okita, K., Miuchi, M., Konya, H., Hamaguchi, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0737-6 · Cited by 83
Blandino-Rosano, M., Perez-Arana, G., Mellado-Gil, J. M., Segundo, C., & Aguilar-Diosdado, M. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0154 · Cited by 82
Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans
Meier, J. J., Butler, A. E., Galasso, R., RIZZA, R. A., & Butler, P. C. (2006) · Diabetologia · doi:10.1007/s00125-006-0410-5 · Cited by 77
Figeac, F., Uzan, B., Faro, M., Chelali, N., Portha, B., & Movassat, J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00538.2009 · Cited by 75
Self-citationWideman, R. D., Covey, S. D., Webb, G. C., Drucker, D. J., & Kieffer, T. J. (2007) · Diabetes · doi:10.2337/db07-0563 · Cited by 74
Xie, T., Chen, M., Zhang, Q., Ma, Z., & Weinstein, L. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704796104 · Cited by 72
Kwan, E. P., Xie, L., Sheu, L., Ohtsuka, T., & Gaisano, H. Y. (2007) · Diabetes · doi:10.2337/db06-1207 · Cited by 71
Integration of ATP, cAMP, and Ca2+ signals in insulin granule exocytosis.
Shibasaki, T., Sunaga, Y., & Seino, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s59 · Cited by 66
Peyot, M., Gray, J. P., Lamontagne, J., Smith, P. J., Holz, G. G., Madiraju, S. R. M., Prentki, M., & Heart, E. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006221 · Cited by 64
Pugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G., & Pugazhenthi, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1849-y · Cited by 61
Successful Islet Transplantation for Patients with Diabetes — Fact or Fantasy?
Robertson, R. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430409 · Cited by 61
Exendin-4 induction of cyclin D1 expression in INS-1 β-cells: involvement of cAMP-responsive element
Kim, M.-J., Kang, J.-H., Park, Y. G., Ryu, G. R., Ko, S. H., Jeong, I.-K., Koh, K.-H., Rhie, D.-J., Yoon, S. H., Hahn, S. J., et al. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06480 · Cited by 60
Chepurny, O. G., Hussain, M. A., & Holz, G. G. (2002) · Endocrinology · doi:10.1210/endo.143.6.8870 · Cited by 55
Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes
Yang, Z., Chen, M., Carter, J. D., Nunemaker, C. S., Garmey, J. C., Kimble, S. D., & Nadler, J. L. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.177 · Cited by 50
Effects of exendin‐4 on islets from type 2 diabetes patients
Lupi, R., Mancarella, R., Del Guerra, S., Bugliani, M., Del Prato, S., Boggi, U., Mosca, F., Filipponi, F., & Marchetti, P. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00838.x · Cited by 47
Involvement of PDX-1 in activation of human insulin gene transcription
Lay, J. E. L., & Stein, R. W. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06510 · Cited by 43
Dachicourt, N., Serradas, P., Bailbé, D., Kergoat, M., Doaré, L., & Portha, B. (1997) · Journal of Endocrinology · doi:10.1677/joe.0.1550369 · Cited by 40
Self-citationYew, K.-H., Hembree, M. J., Prasadan, K. L., Preuett, B. L., McFall, C. R., Benjes, C. L., Crowley, A. R., Sharp, S. W., Tulachan, S., Mehta, S. S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505465200 · Cited by 39
cAMP-secretion coupling is impaired in diabetic GK/Par rat β-cells: a defect counteracted by GLP-1.
Dolz, M., Movassat, J., Bailbe, D., le Stunff, H., Giroix, M., Fradet, M., Kergoat, M., & Portha, B. (2011) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.00652.2010 · Cited by 31
Self-citationPérez-Arana, G.-M., Blandino-Rosano, M., Oliveira, J. A. P., Aguilar‐Diosdado, M., & Segundo, C. (2010) · Endocrinology · doi:10.1210/en.2009-1113 · Cited by 21
Synergistic Endocrine Induction by GLP-1 and TGF-?? in the Developing Pancreas
Tei, E., Mehta, S. S., Tulachan, S., Yew, H., Hembree, M. J., Preuett, B. L., Snyder, C. L., Yamataka, A., Miyano, T., & Gittes, G. K. (2005) · Pancreas · doi:10.1097/01.mpa.0000172566.70619.58 · Cited by 19
Synergistic endocrine induction by GLP-1 and TGF-β in the developing pancreas
鄭, 英. (2006) · Medical Entomology and Zoology · Cited by 4
Research works printed but not linked: 6
- 10.1210/en.143.6.2303 · doi:10.1210/en.143.6.2303
- 10.1210/en.142.3.1218 · doi:10.1210/en.142.3.1218
- 2000, Journal of Clinical Endocrinology and Metabolism, 85, 3892
- 10.1002/(SICI)1097-4652(199912)181:3<470::AID-JCP11>3.0.CO;2-P · DOI · Paper page
- 2002, American Journal of Physiology, 283, E745
- 2008, The New England Journal of Medicine, 358, 1970
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“AD rodent models chronically treated with the GLP-1 analog Val(8)glucagonlike peptide-1 caused modulation of neurotransmitter release, synaptic transmission (LTP) formation, and restoration of synaptic plasticity, as well as preventing impairment in the learning of new spatial tasks (328–330).”
BackgroundRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Jakubowicz, D., & Froy, O. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.07.008 · Cited by 246
Metadata
- Authors
- Portha, B., Tourrel-Cuzin, C., & Movassat, J.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Laboratoire B2PE (Biologie et Pathologie du Pancréas Endocrine), Unité BFA (Biologie Fonctionnelle et Adaptive), Equipe 1, Université Paris-Diderot et CNRS EAC 4413, Bâtiment BUFFON, 5ème étage, pièce 552A, 4, Rue Lagroua Weill Hallé, Case 7126, 75205 Paris Cedex 13, France
- Corresponding author
- Portha, Bernard
- ORCID
- Movassat, Jamileh
- Venue
- Experimental Diabetes Research
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-11
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3118608
- OpenAlex
- W2091979481
- Cited by
- 85
- References
- 110
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 9 · 2012: 11
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Centre National de la Recherche Scientifique
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- GLP-1 receptor agonists, DPP-4 inhibitors, beta-cell mass, beta-cell neogenesis, beta-cell proliferation, beta-cell survival, type 2 diabetes, islet mass
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Cell Transformation, Neoplastic, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Humans, Middle Aged, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Receptors, Glucagon, Insulin-Secreting Cells, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.